Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.61 |
| ▸ | JAK3 | P52333 | 6/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | TEC | P42680 | 1/20 | 0.46 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645831 | 0.93 | BTK (0.60) | BTKJAK3PAK1EGFRJAK2 | |
| SCHEMBL19645826 | 0.93 | BTK (0.60) | BTKJAK3PAK1EGFRJAK2 | |
| SCHEMBL17359437 | 0.92 | BTK (0.60) | BTKJAK3PAK1EGFRJAK2 | |
| SCHEMBL19645828 | 0.91 | BTK (0.58) | BTKJAK3PAK1EGFRJAK2 | |
| SCHEMBL17071369 | 0.91 | BTK (0.63) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL17071368 | 0.90 | BTK (0.66) | BTKJAK3EGFRJAK2JAK1 | |
| SCHEMBL19645821 | 0.88 | BTK (0.79) | BTKJAK3PAK1EGFRJAK2 | |
| SCHEMBL17071262 | 0.88 | BTK (0.48) | BTKJAK3PAK1EGFRSRC | |
| SCHEMBL17359433 | 0.88 | BTK (0.56) | BTKJAK3PAK1EGFRJAK2 | |
| SCHEMBL22213221 | 0.86 | BTK (0.52) | BTKJAK3PAK1EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885JAK3 58/4885PAK1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.